Lipocine’s weight loss drug shows early signs of keeping muscle mass in Ph2
Although Lipocine’s candidate may have delivered “modest” weight loss results, the company nonetheless touted its ability to preserve muscle mass in a mid-stage trial. It noted that the drug might be best positioned as an adjunct to incretin products, such as GLP-1s.
The drug, LPCN 2401, contains an anabolic androgen receptor agonist and the antioxidant metabolic modifier α-alpha tocopherol. It has the potential to attenuate weight rebound, mitigate loss of muscle mass and boost muscle quality when added to an incretin, Lipocine said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
